India's First MRNA COVID-19 Vaccine Phase-I Clinical Trial Gets Nod

[email protected]21 Sep, 2021News

The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study. "Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted for the phase 2 and 3 studies by Gennova Biopharmaceuticals Limited, a Pune-based biotechnology company," the Ministry of Science and Technology said in a release on Tuesday.

Recent Profiles

AA 88

Aa 88

View Profile

ONE88

One88

View Profile

Larsen Crockett

Larsen Crockett

View Profile

Leading Edge Drywall and Construction

Leading Edge Drywall And Construction

View Profile

Blaabjerg Chung

Blaabjerg Chung

View Profile

Broussard Scott

Broussard Scott

View Profile

SpinXpress Laundry - Pioneer

Spinxpress Laundry - Pioneer

View Profile